Literature DB >> 21252669

Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.

Mitchell E Horwitz1.   

Abstract

PURPOSE OF REVIEW: Use of a reduced intensity conditioning (RIC) regimen has now become standard practice among older or more infirmed stem cell transplantation candidates. Encouraging outcome in this population has led to the question of whether RIC should replace standard myeloablative conditioning (MAC) regimens. This review will summarize the available outcomes data comparing RIC and MAC approaches to stem cell transplantation in adult patients with acute myeloid leukemia, myelodysplastic syndrome (MDS) and acute lymphoid leukemia. RECENT
FINDINGS: There are currently no completed prospective randomized controlled studies comparing outcomes of RIC to MAC. The best insight into differences in outcome comes from large registry-based retrospective studies. These studies demonstrate that the use of RIC is associated with a reduction in transplant-related mortality but an increased risk of disease relapse. As a result, for patients undergoing stem cell transplantation in remission, disease free and overall survival are similar.
SUMMARY: The current retrospective data provide justification for the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in remission and MDS. More definitive conclusions regarding differences between the MAC and RIC approach to stem cell transplantation await results of ongoing prospective randomized trials.

Entities:  

Mesh:

Year:  2011        PMID: 21252669     DOI: 10.1097/CCO.0b013e328342b82a

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  17 in total

1.  Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 3.  Survivorship after allogeneic transplantation-management recommendations for the primary care provider.

Authors:  André Tichelli; Alicia Rovó
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 4.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

5.  Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review.

Authors:  Wen Zeng; Lifang Huang; Fankai Meng; Zeming Liu; Jianfeng Zhou; Hanying Sun
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 6.  Bone management in hematologic stem cell transplant recipients.

Authors:  D L Kendler; J J Body; M L Brandi; R Broady; J Cannata-Andia; M J Cannata-Ortiz; A El Maghraoui; G Guglielmi; P Hadji; D D Pierroz; T J de Villiers; R Rizzoli; P R Ebeling
Journal:  Osteoporos Int       Date:  2018-09-03       Impact factor: 4.507

7.  Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Authors:  Junya Kanda; Gwynn D Long; Cristina Gasparetto; Mitchell E Horwitz; Keith M Sullivan; John P Chute; Ashley Morris; Michael Shafique; Zhiguo Li; Nelson J Chao; David A Rizzieri
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-20       Impact factor: 5.742

Review 8.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.

Authors:  Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele
Journal:  Nat Rev Clin Oncol       Date:  2012-09-04       Impact factor: 66.675

Review 9.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

10.  Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Authors:  Rachel B Salit; Daniel H Fowler; Robert M Dean; Steven Z Pavletic; Frances T Hakim; Seth M Steinberg; Nancy T Hardy; Claude Sportes; Ronald E Gress; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.